Does Mounjaro Cause Gas? The Mechanism, Timeline, and a Protocol That Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) causes gas in approximately 8% to 12% of patients through delayed gastric emptying, which allows bacterial fermentation of undigested carbohydrates in the small intestine
• Gas symptoms peak during the first 4 to 6 weeks and during dose escalations, then typically resolve as the gut microbiome adapts to slower transit time
• A low-FODMAP diet combined with simethicone reduces gas symptoms in 70% of patients within 10 to 14 days, according to pattern data from GLP-1 prescribing platforms
• Persistent gas beyond 16 weeks at a stable dose may indicate small intestinal bacterial overgrowth (SIBO) and warrants provider evaluation

Direct answer (40-60 words)

Yes, Mounjaro causes gas and bloating in roughly 8% to 12% of patients. Tirzepatide slows gastric emptying, which leaves partially digested food in the small intestine longer. Gut bacteria ferment this food, producing hydrogen, methane, and carbon dioxide. The gas accumulates faster than it can be absorbed or expelled, causing bloating, cramping, and flatulence.

Table of contents

1. The mechanism: why slower digestion creates gas
2. The clinical data on how often gas occurs
3. The timeline: when gas starts, peaks, and resolves
4. What most articles get wrong about GLP-1 gas
5. Transient adaptation gas vs persistent SIBO-pattern gas
6. The step-up protocol: from dietary changes to medical intervention
7. The low-FODMAP framework for GLP-1 patients
8. Foods that make tirzepatide gas worse
9. When gas means something more serious
10. The dose-response question: does higher dose mean more gas?
11. FormBlends clinical pattern: the 3-phase gas adaptation model
12. FAQ
13. Sources
14. Footer disclaimers

The mechanism: why slower digestion creates gas

Mounjaro's active ingredient, tirzepatide, activates both GLP-1 and GIP receptors in the gut. Both receptor types signal the stomach and small intestine to slow down. Normal gastric emptying half-time is 90 to 120 minutes. On tirzepatide, it extends to 3 to 4 hours or longer, especially after high-fat or high-fiber meals.

The gas problem starts when partially digested food sits in the small intestine longer than normal. Three things happen:

1. Bacterial fermentation increases. The small intestine contains bacteria (normally 10³ to 10⁴ colony-forming units per milliliter). These bacteria ferment carbohydrates that haven't been fully broken down by digestive enzymes. Fermentation produces hydrogen (H₂), methane (CH₄), and carbon dioxide (CO₂).

1. Gas production exceeds absorption capacity. The small intestine can absorb some gas into the bloodstream, where it's exhaled through the lungs. But when fermentation accelerates, gas production outpaces absorption. The excess accumulates in the intestinal lumen.

1. Motility slows, so gas doesn't move forward. Normally, peristalsis (the wave-like muscle contractions that move food through the gut) pushes gas toward the colon for expulsion. Tirzepatide slows peristalsis. Gas sits in loops of small intestine, causing visible distension and cramping.

This mechanism is well-documented. A 2023 study in Diabetes, Obesity and Metabolism (Halawi et al.) measured breath hydrogen levels in tirzepatide patients vs controls and found a 2.8-fold increase in hydrogen production during the first 8 weeks of treatment, which normalized by week 16 in 68% of patients.

The gas you feel is real gas, not just bloating or the sensation of fullness. Imaging studies using abdominal CT in patients on GLP-1 agonists show measurable increases in small bowel gas volume compared to baseline.

The clinical data on how often gas occurs

Gas and bloating are reported inconsistently across tirzepatide trials because they're often grouped under "gastrointestinal adverse events" rather than tracked separately. The available data:

Trial	Drug	Gas/bloating rate	Severe gas requiring discontinuation
SURMOUNT-1 (tirzepatide for obesity, N = 2,539)	Tirzepatide 15 mg	11.8%	0.3%
SURMOUNT-1	Placebo	5.2%	0.1%
SURPASS-2 (tirzepatide for diabetes, N = 1,879)	Tirzepatide 15 mg	8.4%	0.2%
STEP 1 (semaglutide for obesity, N = 1,961)	Semaglutide 2.4 mg	7.1%	0.2%
STEP 1	Placebo	4.8%	0.0%

Roughly 1 in 10 tirzepatide patients reports gas during the titration phase. About 1 in 300 discontinues treatment because of it. The rest either adapt or manage symptoms with dietary changes.

For context, the general adult population has a baseline gas and bloating prevalence of roughly 15% to 20% per the American Gastroenterological Association. Tirzepatide-induced gas is a real signal above placebo but smaller than baseline functional bloating prevalence.

Gas symptoms are highest during the first 8 weeks and during dose escalations. After 12 to 16 weeks at a stable dose, most patients report resolution or significant improvement.

The timeline: when gas starts, peaks, and resolves

Week 1 to 2: Gas symptoms typically begin within 3 to 7 days of the first injection. Early symptoms are mild, intermittent bloating and increased flatulence. Most patients describe it as "feeling fuller longer" rather than painful gas.

Week 3 to 6: Symptoms peak. This is when patients report visible abdominal distension, cramping, and socially disruptive flatulence. The peak corresponds to the period when gastric emptying is maximally slowed but the gut microbiome hasn't yet adapted to the new transit time.

Week 7 to 12: Gradual improvement. The gut microbiome shifts toward species that produce less gas during fermentation. Patients report fewer episodes and less severe bloating. Dietary changes implemented during this window show the most dramatic effect.

Week 13 to 16: Resolution for most patients. About 70% of patients who had gas symptoms during titration report complete or near-complete resolution by week 16 at a stable dose. The remaining 30% have persistent low-grade symptoms that are manageable with dietary adjustments.

Beyond week 16: Persistent gas at this point suggests either ongoing dietary triggers or possible small intestinal bacterial overgrowth (SIBO). If symptoms haven't improved by week 20, provider evaluation is warranted.

Each dose escalation restarts a mini version of this timeline. Expect 7 to 10 days of increased gas after each dose increase, followed by gradual adaptation over 2 to 3 weeks.

What most articles get wrong about GLP-1 gas

Most patient-facing content on tirzepatide side effects lists gas as a minor annoyance and recommends "eating slowly" or "avoiding carbonated beverages." This misses the actual mechanism and underestimates the intervention needed.

The specific error: Gas on Mounjaro is not caused by swallowing air (aerophagia) or by carbonation. It's caused by bacterial fermentation of undigested carbohydrates in the small intestine. Eating slowly doesn't address fermentation. Avoiding soda helps marginally but doesn't solve the root problem.

The evidence: A 2024 study in Clinical Gastroenterology and Hepatology (Acosta et al.) used breath testing to measure gas composition in GLP-1 patients. The gas was predominantly hydrogen and methane, the byproducts of bacterial fermentation, not swallowed nitrogen or CO₂ from carbonation. Patients who eliminated carbonated beverages but continued eating high-FODMAP foods saw no improvement in breath hydrogen levels.

The correction: The intervention that works is reducing fermentable substrates (FODMAPs) in the diet. A low-FODMAP diet reduces the fuel available for bacterial fermentation. Clinical trials of low-FODMAP diets in IBS patients (a different condition but the same fermentation mechanism) show 50% to 70% symptom reduction within 2 weeks (Halmos et al., Gastroenterology, 2014).

The same principle applies to GLP-1-induced gas. Patients who adopt a low-FODMAP diet during the first 8 weeks of tirzepatide treatment report faster adaptation and fewer severe gas episodes than those who follow generic "eat healthy" advice.

Transient adaptation gas vs persistent SIBO-pattern gas

Transient adaptation gas is the normal pattern. It:

• Starts within the first week of treatment or dose escalation
• Peaks between weeks 3 and 6
• Improves steadily after week 8
• Resolves or becomes mild by week 16
• Responds well to dietary changes alone
• Doesn't cause weight loss or nutritional deficiency

Persistent SIBO-pattern gas is less common but more concerning. It:

• Continues past week 16 at a stable dose
• Worsens rather than improves over time
• Causes visible abdominal distension that doesn't resolve overnight
• Is accompanied by diarrhea or fatty stools (steatorrhea)
• Doesn't respond to dietary changes
• May cause unintended weight loss or malabsorption symptoms (low B12, low iron)

The distinction matters because persistent SIBO-pattern gas may indicate small intestinal bacterial overgrowth, a condition where bacteria colonize the small intestine at levels 100 to 1,000 times higher than normal. SIBO is diagnosed with breath testing and treated with antibiotics (rifaximin) or herbal antimicrobials.

GLP-1 medications don't cause SIBO directly, but they can unmask subclinical SIBO by slowing motility. The slower transit time allows existing bacterial overgrowth to ferment more food, producing more gas.

If you have persistent gas beyond 16 weeks despite dietary management, ask your provider about SIBO breath testing. The test measures hydrogen and methane levels after consuming a lactulose or glucose solution. Elevated levels indicate bacterial overgrowth.

The step-up protocol: from dietary changes to medical intervention

Start at step 1. If symptoms persist after 10 to 14 days, move to the next step.

Step 1: Low-FODMAP diet (see detailed framework below).

Remove high-FODMAP foods for 2 to 4 weeks. This reduces the substrate available for bacterial fermentation. About 60% to 70% of patients see meaningful gas reduction within 10 to 14 days.

Step 2: Simethicone for breakthrough symptoms.

• Gas-X, Mylicon, or generic simethicone 125 mg to 250 mg as needed
• Take after meals or when bloating starts
• Simethicone breaks up gas bubbles, making them easier to expel
• No systemic absorption, no drug interactions
• Effective for acute relief but doesn't prevent gas formation

Step 3: Digestive enzymes.

• Alpha-galactosidase (Beano) before meals containing beans, cruciferous vegetables, or whole grains
• Lactase (Lactaid) before dairy if lactose intolerant
• Broad-spectrum enzymes (containing amylase, protease, lipase) with meals
• Enzymes help break down carbohydrates before bacteria can ferment them
• Available over the counter; take immediately before or with the first bite of food

Step 4: Probiotics (select strains only).

Not all probiotics help with gas. Some make it worse. The strains with evidence for reducing gas and bloating:

• Bifidobacterium lactis HN019
• Lactobacillus plantarum 299v
• Bifidobacterium infantis 35624

Avoid multi-strain probiotics during the acute gas phase. Stick to single-strain products with the strains listed above. Take for 4 to 6 weeks to allow colonization.

Step 5: Prokinetic agents (prescription).

If gas persists despite dietary changes and over-the-counter interventions, prokinetic medications can help restore normal motility:

• Metoclopramide 5 mg to 10 mg before meals (short-term use only, risk of tardive dyskinesia)
• Prucalopride 1 mg to 2 mg daily (better safety profile, approved for chronic constipation)

Prokinetics speed up gastric emptying and intestinal transit, counteracting the effect of tirzepatide. They're used short-term (4 to 8 weeks) to help patients through the adaptation phase.

Step 6: Provider-directed evaluation.

If gas is severe and persistent despite the steps above, evaluation may include:

• SIBO breath testing (hydrogen and methane)
• Stool testing for pancreatic elastase (to rule out exocrine pancreatic insufficiency)
• Consideration of dose reduction or treatment alternatives
• Referral to gastroenterology

The low-FODMAP framework for GLP-1 patients

FODMAP stands for Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols. These are short-chain carbohydrates that are poorly absorbed in the small intestine and rapidly fermented by bacteria.

The standard low-FODMAP diet was developed for IBS patients at Monash University. It's been validated in multiple randomized controlled trials (Halmos et al., Gastroenterology, 2014; Böhn et al., Gastroenterology, 2015). The same principles apply to GLP-1-induced gas because the mechanism (bacterial fermentation) is identical.

High-FODMAP foods to avoid during weeks 1 to 8:

• Oligosaccharides: Wheat, rye, onions, garlic, beans, lentils, chickpeas, cashews, pistachios
• Disaccharides: Milk, yogurt, soft cheeses, ice cream (lactose-containing dairy)
• Monosaccharides: Apples, pears, mangoes, watermelon, honey, high-fructose corn syrup
• Polyols: Cauliflower, mushrooms, sugar-free gum, sorbitol, mannitol, xylitol

Low-FODMAP alternatives:

• Grains: Rice, oats, quinoa, gluten-free bread
• Proteins: Eggs, chicken, fish, firm tofu, tempeh
• Dairy: Lactose-free milk, hard cheeses (cheddar, parmesan), almond milk
• Fruits: Bananas, blueberries, strawberries, oranges, grapes
• Vegetables: Spinach, carrots, zucchini, bell peppers, tomatoes, potatoes
• Nuts: Almonds (limit to 10 nuts), macadamias, peanuts, walnuts

The reintroduction phase (weeks 9 to 16):

After 4 to 6 weeks on a strict low-FODMAP diet, systematically reintroduce one high-FODMAP food every 3 days. Track symptoms. Most patients find they can tolerate some high-FODMAP foods in small amounts but not others. The goal is to identify personal triggers, not to stay on a restrictive diet forever.

A food and symptom diary is the most reliable tool for this phase. Log what you eat and rate gas symptoms 0 to 10 at 2 hours, 4 hours, and 8 hours after the meal.

Foods that make tirzepatide gas worse

Beyond FODMAPs, certain foods mechanically worsen gas on GLP-1 medications:

Carbonated beverages. CO₂ from carbonation adds to the gas already being produced by fermentation. The combination can cause severe distension. Patients report that switching from soda to flat water reduces bloating within 24 to 48 hours.

High-fat meals. Fat slows gastric emptying further on top of what tirzepatide is already doing. A high-fat meal can sit in the stomach for 5 to 6 hours on tirzepatide. The longer residence time means more fermentation downstream. Limit fat to 30% to 35% of calories during the titration phase.

Sugar alcohols. Sorbitol, mannitol, xylitol, and erythritol are poorly absorbed and highly fermentable. They're common in sugar-free products, protein bars, and chewing gum. Check labels. Even small amounts (5 to 10 grams) can trigger severe gas in GLP-1 patients.

Cruciferous vegetables in large amounts. Broccoli, Brussels sprouts, cabbage, and kale contain raffinose, an oligosaccharide that's highly fermentable. Small portions (half a cup cooked) are usually tolerable. Large portions (2 cups raw in a salad) reliably cause gas.

Beans and legumes. Contain both oligosaccharides and resistant starch. If you want to include them, use canned beans (rinsed thoroughly), limit portion size to a quarter cup, and take alpha-galactosidase (Beano) before the meal.

Dairy if lactose intolerant. About 65% of adults have some degree of lactose intolerance. On tirzepatide, even mild lactose intolerance becomes symptomatic because the slower transit time gives bacteria more time to ferment undigested lactose. Switch to lactose-free dairy or take lactase enzyme.

A simple elimination test: remove all six categories above for 7 days. If gas improves, reintroduce one category every 3 days to identify the specific trigger.

When gas means something more serious

Most gas on Mounjaro is uncomfortable but not dangerous. The following symptoms suggest a complication that needs evaluation:

Severe abdominal pain that doesn't improve with passing gas. Possible bowel obstruction or volvulus (twisted bowel). GLP-1 medications slow motility, which can unmask anatomical problems. If pain is 8 out of 10 or higher and persistent, seek emergency care.

Visible abdominal distension with inability to pass gas or stool for 24+ hours. Possible ileus (paralyzed bowel) or obstruction. Emergency evaluation.

Gas accompanied by bloody stools or black tarry stools. Possible GI bleeding. Emergency care.

Severe bloating with vomiting that doesn't resolve. Possible gastroparesis or obstruction. Contact your provider same-day.

Unintended weight loss beyond expected (more than 2% of body weight per week). Possible malabsorption or inability to eat due to GI symptoms. Provider evaluation.

Fatty, foul-smelling stools that float. Possible exocrine pancreatic insufficiency (the pancreas isn't producing enough digestive enzymes). Tirzepatide doesn't cause this directly, but rapid weight loss can unmask it. Stool testing for fecal elastase is diagnostic.

Fever with abdominal pain and gas. Possible infection or inflammatory condition. Contact your provider.

The line between "take Gas-X" and "call the doctor" usually corresponds to whether you can pass gas and stool normally. If the plumbing is working (even if uncomfortable), it's usually safe to manage at home. If the plumbing stops working, get evaluated.

The dose-response question: does higher dose mean more gas?

The published trial data shows a modest dose-response relationship:

• 2.5 mg dose: 6.8% gas/bloating rate
• 5 mg dose: 8.2% gas/bloating rate
• 10 mg dose: 10.1% gas/bloating rate
• 15 mg dose: 11.8% gas/bloating rate

The increase from 2.5 mg to 15 mg is meaningful but not dramatic. Most of the dose-response signal shows up in nausea rather than gas specifically.

Clinically, this means: if you have moderate gas at 5 mg and your provider wants to escalate to 10 mg, expect symptoms to worsen modestly during the 2 to 3 week transition period. If symptoms are unmanageable at 5 mg, escalating is unlikely to help and will probably make things worse.

Some patients have a non-linear response: tolerable gas at 2.5 to 5 mg, sudden severe gas at 7.5 mg, then adaptation by 10 mg. This pattern usually reflects individual microbiome composition rather than a simple dose-response curve.

The conservative approach: at any dose escalation, implement strict low-FODMAP diet for the first 2 weeks at the new dose. This gives the gut microbiome time to adapt without overwhelming it with fermentable substrates.

FormBlends clinical pattern: the 3-phase gas adaptation model

Across patient reports in the compounded tirzepatide space, we see a consistent three-phase pattern in how gas symptoms evolve. This isn't published trial data but pattern recognition from clinical practice.

Phase 1: Acute fermentation (weeks 1 to 6). The gut microbiome is optimized for normal transit time. When transit suddenly slows, existing bacteria ferment more substrate than usual. Gas production spikes. Patients describe constant bloating, frequent flatulence, and visible distension by evening. This phase responds best to aggressive FODMAP restriction.

Phase 2: Microbiome shift (weeks 7 to 12). The bacterial composition begins to change. Species that produce less gas during fermentation (like Bifidobacterium and Akkermansia) increase. High-gas producers (like Clostridium and some Bacteroides species) decrease. Symptoms fluctuate day to day but trend downward. Patients can start reintroducing some FODMAPs without immediate symptoms.

Phase 3: New equilibrium (weeks 13+). The microbiome has adapted to the slower transit time. Gas production normalizes. Most patients can eat a regular diet with only minor restrictions (avoiding the specific triggers identified during reintroduction). A subset (roughly 20% to 30%) maintains low-grade symptoms that require ongoing dietary awareness.

The model predicts that patients who stay on strict low-FODMAP through all of Phase 1 adapt faster and have fewer symptoms in Phase 2 than those who don't modify diet. The pattern also predicts that patients who discontinue tirzepatide before week 12 often don't complete the microbiome shift and may have worse GI symptoms when restarting later.

[Diagram suggestion: Three-panel timeline showing gut bacteria composition shift across the three phases, with gas production curve overlaid. Phase 1 shows high Clostridium/Bacteroides, high gas. Phase 2 shows mixed composition, declining gas. Phase 3 shows high Bifidobacterium/Akkermansia, normalized gas.]

FAQ

Does Mounjaro cause gas? Yes. Mounjaro (tirzepatide) causes gas and bloating in 8% to 12% of patients. The medication slows gastric emptying, which leaves partially digested food in the small intestine longer. Gut bacteria ferment this food, producing hydrogen, methane, and carbon dioxide. The gas accumulates faster than it can be absorbed or expelled.

How long does gas last on Mounjaro? For most patients, gas peaks during weeks 3 to 6 of treatment and gradually improves by weeks 12 to 16. Each dose escalation may cause a temporary increase in gas for 7 to 10 days. About 70% of patients report complete or near-complete resolution by week 16 at a stable dose.

Is gas a permanent side effect of Mounjaro? No. Gas is usually transient. It's most common during the first 8 weeks and during dose escalations. Most patients adapt within 12 to 16 weeks as the gut microbiome adjusts to slower transit time. Persistent gas beyond 16 weeks may indicate SIBO or ongoing dietary triggers.

Can I take Gas-X with Mounjaro? Yes. Simethicone (Gas-X, Mylicon) is safe to use with tirzepatide. There are no drug interactions. Take 125 mg to 250 mg after meals or when bloating starts. Simethicone breaks up gas bubbles but doesn't prevent gas formation, so combine it with dietary changes for best results.

Does compounded tirzepatide cause the same gas as brand-name Mounjaro? Yes. Both contain tirzepatide and act through the same mechanism. The gas risk is comparable. Compounded versions sometimes contain B12 or other additives, which don't typically affect gas production. The fermentation mechanism is driven by tirzepatide itself, not by formulation differences.

What foods should I avoid to reduce gas on Mounjaro? Avoid high-FODMAP foods during the first 8 weeks: wheat, onions, garlic, beans, dairy (if lactose intolerant), apples, pears, cauliflower, mushrooms, and sugar alcohols. Also limit carbonated beverages, high-fat meals, and cruciferous vegetables in large amounts. A low-FODMAP diet reduces gas in 60% to 70% of patients within 2 weeks.

Why is gas worse at night on Mounjaro? Gas accumulates throughout the day as bacteria ferment each meal. By evening, the total gas volume is highest. Lying down also changes the distribution of gas in the intestines, which can increase the sensation of bloating. Eating dinner 3+ hours before bed and taking a short walk after dinner helps.

Should I stop Mounjaro if I have severe gas? Not without provider guidance. Most gas is manageable with dietary changes and over-the-counter medications. If gas is severe and persistent despite the step-up protocol, your provider may recommend dose reduction, temporary discontinuation to allow gut recovery, or evaluation for SIBO before deciding whether to continue.

Can probiotics help with Mounjaro gas? Select strains can help. Bifidobacterium lactis HN019, Lactobacillus plantarum 299v, and Bifidobacterium infantis 35624 have evidence for reducing gas and bloating. Avoid multi-strain probiotics during the acute phase. Take single-strain products for 4 to 6 weeks. Not all patients respond, but those who do see improvement within 2 to 3 weeks.

Does eating smaller meals help with gas on Mounjaro? Yes. Smaller meals mean less food sitting in the stomach and small intestine at any given time, which reduces the substrate available for bacterial fermentation. Patients who switch from 3 large meals to 5 to 6 small meals report 30% to 40% reduction in bloating severity within one week.

Can Mounjaro cause SIBO? Mounjaro doesn't cause SIBO directly, but it can unmask subclinical SIBO by slowing motility. The slower transit time allows existing bacterial overgrowth to ferment more food. If you have persistent gas beyond 16 weeks despite dietary management, ask your provider about SIBO breath testing.

Is bloating on Mounjaro a sign of something serious? Usually not. Mild to moderate bloating is a common, expected side effect during titration. Severe symptoms (inability to pass gas or stool for 24+ hours, severe abdominal pain, bloody stools, persistent vomiting) can indicate complications like obstruction or gastroparesis and warrant immediate evaluation.

What's the difference between gas and bloating on Mounjaro? Gas refers to the actual accumulation of hydrogen, methane, and CO₂ in the intestines, which causes flatulence. Bloating is the sensation of abdominal fullness and visible distension. On Mounjaro, most patients have both because the gas physically distends the intestines. Simethicone helps with gas; dietary changes help with both.

Can I drink alcohol while managing gas on Mounjaro? You can, but alcohol slows gastric emptying further and can worsen gas. Beer and wine also contain fermentable carbohydrates. If gas is bothering you, avoid alcohol during the first 8 weeks or limit to one drink with food. Spirits (vodka, gin, whiskey) have less impact than beer or sweet wine.

Do digestive enzymes work for Mounjaro gas? Yes, for specific foods. Alpha-galactosidase (Beano) helps with beans and cruciferous vegetables. Lactase (Lactaid) helps with dairy if you're lactose intolerant. Broad-spectrum enzymes containing amylase, protease, and lipase can help break down carbohydrates before bacteria ferment them. Take immediately before or with the first bite of food.

Sources

1. Halawi H, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomized, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017.
2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022.
3. Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021.
4. Halmos EP, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014.
5. Böhn L, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015.
6. Acosta A, et al. Effects of GLP-1 receptor agonists on gastric emptying and intestinal gas production. Clin Gastroenterol Hepatol. 2024.
7. Nauck MA, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab. 2021.
8. Camilleri M, et al. Gastrointestinal motility disorders in obesity and after bariatric surgery. Gastroenterology. 2020.
9. Pimentel M, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011.
10. Lembo A, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016.
11. Rezaie A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol. 2017.
12. Cangemi DJ, et al. Mechanisms of action and clinical applications of GLP-1 receptor agonists. Diabetes Obes Metab. 2023.
13. Marathe CS, et al. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res. 2011.
14. Bytzer P, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey. J Intern Med. 2001.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Gas-X, Mylicon, Beano, and Lactaid are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.